Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 623

Similar articles for PubMed (Select 15945504)

2.

Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.

Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M.

Lung Cancer. 2001 Feb-Mar;31(2-3):213-9.

PMID:
11165400
3.

Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.

Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E.

Cancer Invest. 2006 Oct;24(6):576-80.

PMID:
16982461
4.

[Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].

Zhao J, Liu XY, Zhang QY, Jiang W.

Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):676-9. Chinese.

PMID:
16438890
5.

[Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].

Tang JH, Zhao JH, Gong JP, Qin JW, Pan LQ, Xu ZY.

Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):210-4. Chinese.

PMID:
17649639
6.

Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.

Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G.

Anticancer Res. 1998 Mar-Apr;18(2A):1123-7.

PMID:
9615776
7.

Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.

Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP.

J Thorac Oncol. 2008 Oct;3(10):1119-26. doi: 10.1097/JTO.0b013e318187464e.

PMID:
18827607
8.

Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.

Brattström D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, Brodin O, Wagenius G.

Lung Cancer. 2002 Jul;37(1):57-63.

PMID:
12057868
9.

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.

Naumnik W, Nilklińska W, Ossolińska M, Chyczewska E.

Folia Histochem Cytobiol. 2009;47(4):703-9. doi: 10.2478/v10042-009-0025-z.

10.

Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.

Garpenstrand H, Bergqvist M, Brattström D, Larsson A, Oreland L, Hesselius P, Wagenius G.

Med Oncol. 2004;21(3):241-50.

PMID:
15456951
11.
12.

Circulating angiogenic cytokines in multiple myeloma and related disorders.

Urba ska-Rys H, Wierzbowska A, Robak T.

Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51.

PMID:
12799213
13.

Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.

Tas F, Duranyildiz D, Soydinc HO, Cicin I, Selam M, Uygun K, Disci R, Yasasever V, Topuz E.

Cancer Chemother Pharmacol. 2008 Apr;61(5):721-5. Epub 2007 Jun 7.

PMID:
17554539
14.

Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.

Kurschat P, Eming S, Nashan D, Krieg T, Mauch C.

Br J Dermatol. 2007 Apr;156(4):653-8. Epub 2007 Jan 30.

PMID:
17263813
15.

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

Bremnes RM, Camps C, Sirera R.

Lung Cancer. 2006 Feb;51(2):143-58. Epub 2005 Dec 19. Review.

PMID:
16360975
16.

Serum endostatin levels in patients with lung carcinoma.

Swidzińska E, Ossolińska M, Naumnik W, Trojan S, Chyczewska E.

Rocz Akad Med Bialymst. 2005;50:197-200.

PMID:
16358965
18.

Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.

Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T.

Lupus. 2002;11(6):348-55.

PMID:
12139372
19.

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.

Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T.

Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8.

PMID:
15019676
20.

Serum angiopoietin-2 as a clinical marker for lung cancer.

Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ, Hwang SC.

Chest. 2007 Jul;132(1):200-6. Epub 2007 May 15.

PMID:
17505039
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk